Fosun Pharma's FKC516 Injection Enters Phase II Clinical Trial in China for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Stock News11-12 18:12

Fosun Pharma (02196) has announced that its controlled subsidiary, Fosun Kairui (Shanghai) Biotechnology Co., Ltd., has launched a Phase II clinical trial in China for FKC516 Injection (FKC516) in the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (r/rB-NHL).

FKC516 is a CD20-targeting autologous CAR-T cell therapy product licensed into the group, and the group holds, among other rights, exclusive global rights for development and commercialization across all disease areas in accordance with the agreement.

As of September 2026, the group's cumulative R&D investment in FKC516 amounted to approximately RMB 13.37 million, including licensing fees and unaudited figures.

As of the date of this announcement, November 12, 2026, no CAR-T product targeting the same antigen has been approved for marketing in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment